PEPDIA-PLP-000024

Fig. 2C: CB3-treated animals showed a robust and sustained reduction in seizure frequency throughout the monitoring period.

Fig. 2D: total seizure burden ... was significantly lower in CB3-treated animals than in the vehicle group (p < 0.01).

Fig. 2E: CB3 treatment experience significantly lower seizure duration (p < 0.0001).

Fig. 2F: significantly prolonged latency to the first spontaneous seizure (p < 0.05).

Fig. 2G-H: CB3-treated animals maintained a significantly higher probability of remaining seizure-free across the 84-day period (p < 0.001).

Fig. 3B: CB3 treatment improved locomotor activity, as evident by a significantly greater total distance traveled (p < 0.01).

higher average movement speed (10.74 ± 1.10 cm/s vs 4.73 ± 0.76 cm/s, CB3 vs vehicle; p < 0.01).

CB3-treated animals entered the central area more frequently (16.67 ± 1.26 vs 5.83 ± 1.37, CB3 vs vehicle; p < 0.01).

Fig. 3C: spent a higher percentage of time in the center zone (p < 0.05).

Fig. 3D: CB3-treated animals spent significantly more time in the open arms (p < 0.01).

Fig. 3E: significantly higher entries into the open arms (p < 0.05).

Fig. 3F: No significant differences were observed in the discrimination index (DI) between the two groups.

Fig. 3G: CB3-treated animals showed significantly improved performance (p < 0.05).

Fig. 4B: higher neuronal density in the CB3-treated animals compared to vehicle group (p > 0.01).

Fig. 4C: higher neuronal density in the CB3-treated animals compared to vehicle group (p > 0.01).

Fig. 5B-D: By week 6, seizure frequency in CB3-treated animals was reduced by more than 60% compared to control group (p < 0.001).

Fig. 5D-E: cumulative seizure burden further confirmed that CB3-treated animals experienced fewer seizures than control animals across the study period.

Fig. 6B: CB treatment in chronic phase did not improve locomotor activity, including total travel distance compared with the control group.

Fig. 6C: CB3 treatment influenced anxiety-like behavior, as evidenced by the increased time spent in the center zone compared to control animals (p > 0.05).

Fig. 6D: CB3-treated animals spent significantly more time in the open arms (p < 0.05).

Fig. 6E: the number of open-arm entries did not differ between groups.

Fig. 6F: CB3 treatment did not alter discrimination index values in the novel object recognition test.

Fig. 6G: CB3 treatment did not alter ... performance in the T-maze alternation task.

Fig. 1C: CB3 pretreatment (100 μM, 2 h) significantly inhibits proinflammatory cytokines IL-6 expression.

Fig. 1D: CB3 pretreatment (100 μM, 2 h) significantly inhibits proinflammatory cytokines IL-1β expression.

Fig. 1E: CB3 pretreatment (100 μM, 2 h) significantly inhibits proinflammatory cytokines TNF-α expression.

Fig. 1F: CB3 pretreatment (100 μM, 2 h) ... concomitantly enhanced anti-inflammatory cytokine IL-10 expression.

Fig. 1B: CB3 (50 μM or 100 μM, 2 h) significantly attenuated this fluorescence response in a concentration-dependent manner, reducing signal to ~250% and ~180% of baseline, respectively.

Supp Fig. 2A and C: CB3-treated animals exhibited a significant reduction in 8-OHdG fluorescence intensity in CA1 neurons compared with vehicle-treated animals (p < 0.05).

Supp Fig. 2B and D: no significant differences were observed in the CA3 subfield.